Actively Recruiting
Phase 3 Study of Oral Nizubaglustat AZ-3102 for Late-infantile and Juvenile Niemann-Pick Type C Disease and GM1GM2 Gangliosidosis
Led by Azafaros B.V. · Updated on 2026-10-27
147
Participants Needed
39
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effects of oral nizubaglustat AZ-3102 in children aged 4 years and older with late-infantile or juvenile forms of Niemann-Pick type C disease, GM1 gangliosidosis, or GM2 gangliosidosis. This Phase 3 study is double-blinded, randomized, placebo-controlled, and conducted at multiple centers. It uses a Master Protocol Research Program with different subprotocols for each disease type to evaluate treatment outcomes. Participants are randomly assigned in a 21 ratio to receive either oral nizubaglustat or a matching placebo. The study lasts 18 months and includes separate subprotocols for Niemann-Pick type C disease and for GM1 or GM2 gangliosidosis. Each subprotocol may have additional eligibility criteria and specific safety and efficacy assessments. During the study, participants undergo evaluations defined in their disease-specific subprotocols. Researchers monitor safety and efficacy throughout the 18-month period, tracking the number of participants assigned to each subprotocol. The study aims to gather detailed information on the treatments impact over this timeframe, with continuous monitoring to assess participant health and responses.
CONDITIONS
Brief Title
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
Research Team
P
Patient Advocacy Representative
C
Contact for Healthcare Professionals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here